Suchergebnisse - "Kirchgesner, Julien"

PubPharm (7)

1

Prevalence of anti-TNF contraindications in Crohn's disease : A cross-sectional survey from the GETAID

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Amiot, A. | Seksik, P. | Reimund, J. | +80

2

Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease

enthalten in: Inflammatory bowel diseases | 2022

von Alric, H. | Amiot, A. | Kirchgesner, J. | +6

3

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients : a multicentre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2021

von Wils, P. | Seksik, P. | Stefanescu, C. | +68

CommentIn: Aliment Pharmacol Ther. 2021 Feb;53(3):450-451. - PMID 33428251

4

Ustekinumab for Perianal Crohn's Disease : The BioLAP Multicenter Study From the GETAID

enthalten in: The American journal of gastroenterology | 2020

von Chapuis-Biron, C. | Kirchgesner, J. | Pariente, B. | +23

5

The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2020

von Kassouri, L. | Amiot, A. | Kirchgesner, J. | +6

6

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis : a GETAID multicentre real-world cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Amiot, A. | Filippi, J. | Abitbol, V. | +65

ErratumIn: Aliment Pharmacol Ther. 2020 Nov;52(9):1533. - PMID 33263381

7

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Alric, H. | Amiot, A. | Kirchgesner, J. | +6

CommentIn: Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. - PMID 32656826

1
[1]